Table 1.

Data extraction from studies that examined the effects of cannabinoid exposure on cognition in the context of HIV in non-human animals

Author/year	HIV animal model and subject characteristics	Cannabinoid measure/manipulation	Cognitive assessments	Cognitive domains	Main findings
Jacobs et al. 2019	Mouse—iTat (50% female) 7/group: Tat + /Tat −	Measured CB1R expression	Go/no-go task	Inhibitory-control	Female iTat + mice demonstrated less inhibitory-control compared to male iTat + mice and had higher CB1R expression in mPFC relative to all other groups; Higher infralimbic mPFC CB1R expression correlated with less inhibitory-control
League et al. 2021	Mouse—iTat (100% female)	MAG-L inhibition via MJN110	Discrimination and reversal-learning task	Learning and cognitive flexibility	Initial and reversal-learning was quicker in Tat + mice than in Tat − mice; MJN 110 slowed reversal-learning to Tat- levels
	12/group: Tat +/Tat−
Wang et al. 2022	Rat-hippocampal gpl20 injection (100% male) 8–9/group: control, sham, gpl20	eCB agonist WIN-55,212–2 (3 mg/kg) and/or CB2R antagonist AM630 (1.5 mg/kg) prior to gpl20	Morris water maze	Learning and memory	Prophylactic WIN-55,212–2 treatment attenuated Gpl20-induced spatial memory deficits; WIN-55,212–2 effects were blocked by CB2R antagonist treatment, which also prevented hippocampal gpl20-induced inflammation and apoptosis
Winsauer et al. 2011	Rhesus monkeys (100% males)	Acute THC (0.032–0.32 mg/kg; IM);	Repeated acquisition task	Learning/working memory	Prior to SIV acute THC decreased response-rates without affecting %errors; tolerance developed to chronic THC irrespective of SIV. Chronic THC did not affect viral load but reduced neuropathology, opportunistic infections and inflammation in SIV + animals, and decreased hippocampal CB1R and CB2R expression across all animals (SIV + / −)
	3–4/group: SIV + / − ; THC + / −	Chronic 28-day THC (2×/day; 0.32 mg/kg; IM)